En-tong Yi1, Rui-xia Liu, Yan Wen, Cheng-hong Yin. 1. Department of Infectious Disease and Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Abstract
AIM: To evaluate the antifibrotic effect of telmisartan, an angiotensin II receptor blocker, in bile duct-ligated rats. METHODS: Adult Sprague-Dawley rats were allocated to 3 groups: sham-operated rats, model rats underwent common bile duct ligation (BDL), and BDL rats treated with telmisartan (8 mg/kg, po, for 4 weeks). The animals were sacrificed on d 29, and liver histology was examined, the Knodell and Ishak scores were assigned, and the expression of angiotensin-converting enzyme (ACE) and ACE2 was evaluated with immunohistochemical staining. The mRNAs and proteins associated with liver fibrosis were evaluated using RTQ-PCR and Western blot, respectively. RESULTS: The mean fibrosis score of BDL rats treated with telmisartan was significantly lower than that of the model rats (1.66±0.87 vs 2.13±0.35, P=0.015). However, there was no significant difference in inflammation between the two groups, both of which showed moderate inflammation. Histologically, treatment with telmisartan significantly ameliorated BDL-caused the hepatic fibrosis. Treatment with telmisartan significantly upregulated the mRNA levels of ACE2 and MAS, and decreased the mRNA levels of ACE, angiotensin II type 1 receptor (AT1-R), collagen type III, and transforming growth factor β1 (TGF-β1). Moreover, treatment with telmisartan significantly increased the expression levels of ACE2 and MAS proteins, and inhibited the expression levels of ACE and AT1-R protein. CONCLUSION: Telmisartan attenuates liver fibrosis in bile duct-ligated rats via increasing ACE2 expression level.
AIM: To evaluate the antifibrotic effect of telmisartan, an angiotensin II receptor blocker, in bile duct-ligated rats. METHODS: Adult Sprague-Dawley rats were allocated to 3 groups: sham-operated rats, model rats underwent common bile duct ligation (BDL), and BDL rats treated with telmisartan (8 mg/kg, po, for 4 weeks). The animals were sacrificed on d 29, and liver histology was examined, the Knodell and Ishak scores were assigned, and the expression of angiotensin-converting enzyme (ACE) and ACE2 was evaluated with immunohistochemical staining. The mRNAs and proteins associated with liver fibrosis were evaluated using RTQ-PCR and Western blot, respectively. RESULTS: The mean fibrosis score of BDL rats treated with telmisartan was significantly lower than that of the model rats (1.66±0.87 vs 2.13±0.35, P=0.015). However, there was no significant difference in inflammation between the two groups, both of which showed moderate inflammation. Histologically, treatment with telmisartan significantly ameliorated BDL-caused the hepatic fibrosis. Treatment with telmisartan significantly upregulated the mRNA levels of ACE2 and MAS, and decreased the mRNA levels of ACE, angiotensin II type 1 receptor (AT1-R), collagen type III, and transforming growth factor β1 (TGF-β1). Moreover, treatment with telmisartan significantly increased the expression levels of ACE2 and MAS proteins, and inhibited the expression levels of ACE and AT1-R protein. CONCLUSION:Telmisartan attenuates liver fibrosis in bile duct-ligated rats via increasing ACE2 expression level.
Authors: Liu Yang; Ramón Bataller; Jennyfer Dulyx; Thomas M Coffman; Pere Ginès; Richard A Rippe; David A Brenner Journal: J Hepatol Date: 2005-08 Impact factor: 25.083
Authors: Regina Maria Pereira; Robson Augusto Souza Dos Santos; Mauro Martins Teixeira; Virginia Hora Rios Leite; Lincoln Paiva Costa; Filipi Leles da Costa Dias; Lucíola S Barcelos; Guilherme Birchal Collares; Ana Cristina Simões e Silva Journal: J Hepatol Date: 2006-11-27 Impact factor: 25.083
Authors: Ramón Bataller; Erwin Gäbele; Christopher J Parsons; Terry Morris; Liu Yang; Robert Schoonhoven; David A Brenner; Richard A Rippe Journal: Hepatology Date: 2005-05 Impact factor: 17.425
Authors: G Paizis; C Tikellis; M E Cooper; J M Schembri; R A Lew; A I Smith; T Shaw; F J Warner; A Zuilli; L M Burrell; P W Angus Journal: Gut Date: 2005-09-15 Impact factor: 23.059
Authors: R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman Journal: Hepatology Date: 1981 Sep-Oct Impact factor: 17.425
Authors: Chandana B Herath; Fiona J Warner; John S Lubel; Rachael G Dean; Zhiyuan Jia; Rebecca A Lew; A Ian Smith; Louise M Burrell; Peter W Angus Journal: J Hepatol Date: 2007-04-02 Impact factor: 25.083
Authors: Mario Menk; Jan Adriaan Graw; Clarissa von Haefen; Marco Sifringer; David Schwaiberger; Thomas Unger; Ulrike Steckelings; Claudia D Spies Journal: Inflammation Date: 2015-08 Impact factor: 4.092
Authors: Luciana M A Borém; João F R Neto; Igor V Brandi; Deborah F Lelis; Sergio H S Santos Journal: Hypertens Res Date: 2018-04-10 Impact factor: 3.872